A Novel Squalenoylated Temozolomide Nanoparticle with Long Circulating Properties Reverses Drug Resistance in Glioblastoma DOI Open Access
Jiao Feng,

Chengyong Wen,

Xiao Zhang

и другие.

International Journal of Molecular Sciences, Год журнала: 2025, Номер 26(10), С. 4723 - 4723

Опубликована: Май 15, 2025

Temozolomide (TMZ) remains the frontline chemotherapy for gliomas; yet its clinical efficacy is significantly compromised by inherent instability and emergence of resistance mechanisms. To surmount these challenges, we engineered a squalenoylated TMZ nanoparticle (SQ-TMZ NPs) via conjugation with squalene, enabling enhanced drug stability improved therapeutic potency against glioblastoma cells. The resulting SQ-TMZ NPs exhibited precisely controlled nanoscale architecture (~126 nm), demonstrating exceptional under physiological storage conditions, minimal hemolytic toxicity (<5%). Notably, nanoparticles conferred superior cytotoxicity in TMZ-resistant T98G cells, attributed to amplification intracellular reactive oxygen species (ROS) DNA damage, along MGMT (O-6-methylguanine-DNA methyltransferase) expression suppression. Furthermore, vivo imaging confirmed their efficient blood-brain barrier (BBB) penetration selective tumor accumulation. This study presents transformative approach integrating prodrug self-assembly targeted delivery not only enhance but also decisively reverse resistance, offering compelling advancement.

Язык: Английский

Stimuli-Responsive Polymeric Nanocarriers Accelerate On-Demand Drug Release to Combat Glioblastoma DOI
Muhammad Ismail,

Yibin Wang,

Yundong Li

и другие.

Biomacromolecules, Год журнала: 2024, Номер unknown

Опубликована: Сен. 11, 2024

Glioblastoma multiforme (GBM) is a highly malignant brain tumor with poor prognosis and limited treatment options. Drug delivery by stimuli-responsive nanocarriers holds great promise for improving the modalities of GBM. At beginning review, we highlighted stimuli-active polymeric carrying therapies that potentially boost anti-GBM responses employing endogenous (pH, redox, hypoxia, enzyme) or exogenous stimuli (light, ultrasonic, magnetic, temperature, radiation) as triggers controlled drug release mainly via hydrophobic/hydrophilic transition, degradability, ionizability, etc. Modifying these target ligands further enhanced their capacity to traverse blood-brain barrier (BBB) preferentially accumulate in glioma cells. These unique features lead more effective cancer minimal adverse reactions superior therapeutic outcomes. Finally, review summarizes existing difficulties future prospects treating Overall, this offers theoretical guidelines developing intelligent versatile facilitate precise GBM clinical settings.

Язык: Английский

Процитировано

8
Therapeutic and responsive release mechanisms of polymer drug conjugates with diverse polymer skeletons DOI
Wenjie Zhao,

K. R. Sun,

Jianqin Yan

и другие.

Nano Today, Год журнала: 2024, Номер 59, С. 102526 - 102526

Опубликована: Окт. 22, 2024

Язык: Английский

Процитировано

3
A Novel Squalenoylated Temozolomide Nanoparticle with Long Circulating Properties Reverses Drug Resistance in Glioblastoma DOI Open Access
Jiao Feng,

Chengyong Wen,

Xiao Zhang

и другие.

International Journal of Molecular Sciences, Год журнала: 2025, Номер 26(10), С. 4723 - 4723

Опубликована: Май 15, 2025

Temozolomide (TMZ) remains the frontline chemotherapy for gliomas; yet its clinical efficacy is significantly compromised by inherent instability and emergence of resistance mechanisms. To surmount these challenges, we engineered a squalenoylated TMZ nanoparticle (SQ-TMZ NPs) via conjugation with squalene, enabling enhanced drug stability improved therapeutic potency against glioblastoma cells. The resulting SQ-TMZ NPs exhibited precisely controlled nanoscale architecture (~126 nm), demonstrating exceptional under physiological storage conditions, minimal hemolytic toxicity (<5%). Notably, nanoparticles conferred superior cytotoxicity in TMZ-resistant T98G cells, attributed to amplification intracellular reactive oxygen species (ROS) DNA damage, along MGMT (O-6-methylguanine-DNA methyltransferase) expression suppression. Furthermore, vivo imaging confirmed their efficient blood-brain barrier (BBB) penetration selective tumor accumulation. This study presents transformative approach integrating prodrug self-assembly targeted delivery not only enhance but also decisively reverse resistance, offering compelling advancement.

Язык: Английский

Процитировано

0